November 22, 2019 8:40pm

I keep saying, keep skimming the upside taking profit off the table but, understand it doesn’t last yet, there are still “some” BUYs out there

The sector has gotten muddled luckily, being played by the machine trading

Pre-open indications: 5 HITs

In the short run, values can be pretty senseless if one side or the other decides to be aggressive in their buying or selling.


 

Framing the main takeaway … pricing and volume creates volatility and liquidity!

 

The Dow closed UP +109.33 (+0.39%), the S&P closed UP +6.75 points (+0.22%) and the NASDAQ closed up +13.67 points (+0.16%)

 

The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

  • Friday the IBB closed up +1.11% while the XBI closed up +0.51%
  • Thursday the IBB closed up +0.30% while the XBI closed up +0.16%
  • Wednesday the IBB closed up +0.51% while the XBI closed up +0.28%
  • Tuesday the IBB closed up +2.21% while the XBI closed up +2.18%
  • Monday the IBB closed down -0.26% while the XBI closed up +0.24%

 

The advance/decline line scenario of 45 covered companies:

  • Friday the close was positive with an A/D line of 27/14, 1 flat, 1 reversed merged (HSGX) and 2 acquired;

 

  • Thursday the close was negative with an A/D line of 19/21, 2 flats, 1 reversed merged (HSGX) and 2 acquired;

 

  • Wednesday the close was positive with an A/D line of 23/18, 1 flat, 1 reversed merged (HSGX) and 2 acquired;

 

  • Tuesday the close was positive with an A/D line of 34/11, 1 flat, 1 reversed merged (HSGX) and 2 acquired;

 

  • Monday the close was negative with an A/D line of 18/22, 2 flats, 1 reversed merged (HSGX) and 2 acquired;

 

Henry’omics:

Sector equities and indexes rose slightly on Friday, but posted their first weekly decline in over a month amid lingering worries around US - China trade talks.

For the week, the S&P 500 lost about -0.3% and snapped a six-week winning streak; the Dow declined -0.5% and had for its first one-week pullback in five while the NASDAQ ended a seven-week winning streak, dropping -0.3%.

The investment community is hesitant and uncertain whether the US and China will sign some sort of trade agreement in the coming weeks.

Trade optimism helped lift the major averages to record highs. Over the past month, the S&P 500 and Dow are both up around 4% while the NASDAQ has rallied 5.1%.

From this morning’s “Date Docket”: consumer sentiment for November came in better than expected. The index rose to 96.8 from 95.5 in October. IHS Markit’s gauges for the U.S. services and manufacturing sectors also rose.

 

I believe in the science but, I more firmly believe in making a profit and ROI (return-on-investment) in any portfolio ...!

 

Decliners:

  • Alnylam Pharmaceuticals (ALNY -$4.29 after Thursday’s +$2.99 after Wednesday’s +$7.34, Tuesday’s +$5.20, Monday’s +$0.68 and last Friday’s +$1.59);
  • Sage Therapeutics (SAGE -$2.78);
  • bluebird bio (BLUE -$1.18);
  • Spark Therapeutics (ONCE -$0.10 after Thursday’s  -$0.45);
  • Biostage (BSTG -$0.10);

Incliners:

  • ReNeuron (RENE.L +$+$1.50 after Wednesday’s -$4.00, Tuesday’s -$2.50 and Monday’s +$11.50);
  • CRISPR Therapeutics (CRSP +$2.81 after Thursday’s -$8.03 after an offering was proposed);
  • uniQure (QURE +$1.15 after Thursday’s -$2.64 and Wednesday’s -$1.54);
  • Ionis Pharmaceuticals (IONS +$1.05 after Thursday’s +$0.69 and Wednesday’s +$1.73);
  • Regenxbio (RGNX +$0.71)

 

 

The percentage (%) indicators:

  • Friday’s range of the 27 upside was +0.23% (CLLS) to +24.75% (VSTM +$0.22) while the 14 downside ranged from -0.05% (ONCE) to -4.35% (BSTG); 

 

  • Thursday’s range of the 19 upside was +0.10% (FATE) to +9.35% (SLDB) while the 21 downside ranged from -0.05% (RGNX) to -11.91% (CRSP); 

 

  • Wednesday’s range of the 23 upside was +0.15% (ONCE) to +7.50% (ALNY) while the 18 downside ranged from -0.34% (BMRN) to -3.12% (EDIT); 

 

  • Tuesday’s range of the 34 upside was +0.16% (ONCE) to +16.87% (CRSP) while the 7 downside ranged from -0.13% (AXGN) to -2.11% (CLBS);

 

  • Monday’s range of the 18 upside was +0.01% (BLUE) to +11.50% (RENE.L) while the  22 downside ranged from -0.23% (VYGR) to -4.75% (VSTM);

 

 

Upside volume stats:  to compare

•     Friday: 8 out of the 27 upside had higher than the 3 month average volume;

  • Thursday: 6 out of the 19 upside had higher than the 3 month average volume;
  • Wednesday: 10 out of the 23 upside had higher than the 3 month average volume;
  • Tuesday: 15 out of the 34 upside had higher than the 3 month average volume;
  • Monday: 8 out of the 18 upside had higher than the 3 month average volume;

Downside volume stats:

  • Friday: 6 out of the 14 downside had higher than the 3 month average volume;
  • Thursday: 12 out of the 21 downside had higher than the 3 month average volume;
  • Wednesday: 4 out of the 18 downside had higher than the 3 month average volume;
  • Tuesday: 2 out of the 7 downside had higher than the 3 month average volume;
  • Monday: 5 out of the 22 downside had higher than the 3 month average volume;

 

1 flat – BCLI with 1 reverse merged (HSGX), 2 acquired (AST & OSIR) and Spark Therapeutics’ (ONCE) acquisition by Roche could be soon according to rumors from FTC by year’s end.

 

November’s sessions:

Friday closed POSITIVE with 14 decliners, 27 advancers, 1 flat and 2 acquired (AST & OSIR) and 1 reversed (HSGX);

Thursday closed NEGATIVE with 21 decliners, 19 advancers, 2 flats and 2 acquired (AST & OSIR) and 1 reversed (HSGX);

Wednesday closed POSITIVE with 18 decliners, 23 advancers, 1 flat and 2 acquired (AST & OSIR) and 1 reversed (HSGX);

Tuesday closed POSITIVE with 7 decliners, 34 advancers, 1 flat and 2 acquired (AST & OSIR) and 1 reversed (HSGX);

Monday closed NEGATIVE with 22 decliners, 18 advancers, 2 flats and 2 acquired (AST & OSIR) and 1 reversed (HSGX);

Friday closed POSITIVE with 13 decliners, 26 advancers, 3 flats and 2 acquired (AST & OSIR) and 1 reversed (HSGX);

Thursday closed NEGATIVE with 25 decliners, 17 advancers, 0 flat and 2 acquired (AST & OSIR) and 1 reversed (HSGX);

Wednesday closed NEGATIVE with 29 decliners, 12 advancers, 1 flat and 2 acquired (AST & OSIR) and 1 reversed (HSGX);

Tuesday closed NEGATIVE with 29 decliners, 12 advancers, 1 flat and 2 acquired (AST & OSIR) and 1 reversed (HSGX);

Monday closed NEGAIVE with 27 decliners, 14 advancers, 1 flat and 2 acquired (AST & OSIR) and 1 reversed (HSGX);

Friday closed POSITIVE with 11 decliners, 29 advancers, 2 flats and 2 acquired (AST & OSIR) and 1 reversed (HSGX);

Thursday closed POSITIVE with 18 decliners, 21 advancers, 3 flats and 2 acquired (AST & OSIR) and 1 reversed (HSGX);

Wednesday closed NEGATIVE with 27 decliners, 13 advancers, 2 flats and 2 acquired (AST & OSIR) and 1 reversed (HSGX);

Tuesday closed POSITIVE with 17 decliners, 23 advancers, 2 flats and 2 acquired (AST & OSIR) and 1 reversed (HSGX);

Monday closed NEGATIVE with19 decliners, 22 advancers, 1 flat and 2 acquired (AST & OSIR) and 1 reversed (HSGX);

Friday closed POSITIVE with 7 decliners, 33 advancers, 2 flats and 2 acquired (AST & OSIR) and 1 reversed (HSGX);

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.